Preliminary results from the EXPAND trial show that siponimod significantly reduces disability progression confirmed at three and six months, according to results presented at the annual meeting of the European Committee for Treatment and Research in MS (Kappos et al. ECTRIMS 2016; abstract 250).  Read More

Thursday Edition
Friday Edition

European Committee for Treatment and Research in MS (ECTRIMS), London UK, 14-17 September 2016 – The following summarizes recent studies in primary- and secondary-progressive MS. Read More

Thursday Edition
Saturday Edition

European Committee for Treatment and Research in MS (ECTRIMS), London UK, 14-17 September 2016

The following summarizes studies of disease-modifying therapies presented at ECTRIMS 2016. Read More

Friday Edition
Saturday Edition

European Committee for Treatment and Research in MS (ECTRIMS), London UK, 14-17 September 2016

MS pathogenesis
Clinical course
Genetics

Read More